EMA Backs Options for Broadening Obesity Care in Europe
The European Medicines Agency's Committee for Medicinal Products for Human Use has issued positive opinions to expand obesity and diabetes treatment options in the EU. This includes the introduction of two hybrid liraglutide products and an oral formulation of semaglutide for weight management. These developments aim to broaden the use of GLP-1 receptor agonist therapies across various patient demographics and treatment routes.
- ▪The EMA's CHMP has recommended marketing authorization for Ablymico, a liraglutide product for weight management.
- ▪Liraglutide STADA, another hybrid product, is intended for treating type 2 diabetes in patients aged 10 and older.
- ▪Wegovy, an oral semaglutide formulation, is set to be the first oral GLP-1 receptor agonist for weight management in Europe.
Opening excerpt (first ~120 words) tap to expand
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions that could expand treatment options for obesity, weight management, and diabetes management across the European Union. The decisions include two hybrid liraglutide products and a major label extension for semaglutide introducing an oral formulation for weight management. Together, the opinions point to broader use of GLP-1 receptor agonist-based therapies across different indications, age groups, and routes of administration.AblymicoThe CHMP adopted a positive opinion recommending marketing authorization for Ablymico (liraglutide, STADA Arzneimittel) indicated for weight management as an adjunct to a reduced-calorie diet and increased physical activity.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
